Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada

To investigate a potential risk for multiple sclerosis (MS) after vaccination with Arepanrix, the GlaxoSmithKline AS03-adjuvanted influenza A(H1N1)pdm09 vaccine, we used the provincewide immunization registry for Manitoba, Canada, to match 341,347 persons vaccinated during the 2009 pandemic to 485,9...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmud, Salaheddin M., Bozat-Emre, Songul, Mostaço-Guidolin, Luiz C., Marrie, Ruth Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038732/
https://www.ncbi.nlm.nih.gov/pubmed/29912696
http://dx.doi.org/10.3201/eid2407.161783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038732/
https://www.ncbi.nlm.nih.gov/pubmed/29912696
http://dx.doi.org/10.3201/eid2407.161783

Ejemplares similares